Dose optimisation of antibiotics in children: Application of pharmacokinetics/pharmacodynamics in paediatrics

International Journal of Antimicrobial Agents

Volumn 43, Issue 3, 2014, Pages 223-230

  Downes, Kevin J ^a   Hahn, Andrea ^a   Wiles, Jason ^a   Courter, Joshua D ^a   Vinks, Alexander A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antibiotics; Dose optimisation; Pharmacodynamics; Pharmacokinetics; PK PD

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COLISTIMETHATE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; KETOLIDE; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE OTITIS MEDIA; ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERICIDAL ACTIVITY; BLOOD TOXICITY; BRONCHOPNEUMONIA; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; GRAM NEGATIVE INFECTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEWBORN SEPSIS; OPTIMAL DRUG DOSE; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANTIBIOTICS; DOSE OPTIMISATION; PHARMACODYNAMICS; PHARMACOKINETICS; PK/PD;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; HUMANS;

EID: 84896488342     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.11.006     Document Type: Short Survey

References (83)

1. A.L. Hersh, D.J. Shapiro, A.T. Pavia, and S.S. Shah Antibiotic prescribing in ambulatory pediatrics in the United States Pediatrics 128 2011 1053 1061
2. A. Versporten, M. Sharland, J. Bielicki, N. Drapier, V. Vankerckhoven, H. Goossens ARPEC Project Group Members The Antibiotic Resistance and Prescribing in European Children Project: a neonatal and pediatric antimicrobial Web-based point prevalence survey in 73 hospitals worldwide Pediatr Infect Dis J 32 2013 e242 e253
3. B.J. Anderson, and N.H. Holford Tips and traps analyzing pediatric PK data Paediatr Anaesth 21 2011 222 237
4. G.L. Kearns, S.M. Abdel-Rahman, S.W. Alander, D.L. Blowey, J.S. Leeder, and R.E. Kauffman Developmental pharmacology - drug disposition, action, and therapy in infants and children N Engl J Med 349 2003 1157 1167
5. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300
6. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 10 [quiz 11-12]
7. R.W. Bundtzen, A.U. Gerber, D.L. Cohn, and W.A. Craig Postantibiotic suppression of bacterial growth Rev Infect Dis 3 1981 28 37
8. W.A. Craig, and S.C. Ebert Killing and regrowth of bacteria in vitro: a review Scand J Infect Dis Suppl 74 1990 63 70
9. A. Di Paolo, P. Malacarne, E. Guidotti, R. Danesi, and M. Del Tacca Pharmacological issues of linezolid: an updated critical review Clin Pharmacokinet 49 2010 439 447
10. W.A. Craig Pharmacodynamics of antimicrobials: general concepts and applications C.H. Nightingale, P.G. Ambrose, G.L. Drusano, T. Murakawa, Antimicrobial pharmacodynamics in theory and clinical practice 2nd ed. 2007 CRC Press New York, NY 1 19
11. H. Eagle, R. Fleischman, and M. Levy 'Continuous' vs. 'discontinuous' therapy with penicillin; the effect of the interval between injections on therapeutic efficacy N Engl J Med 248 1953 481 488
12. G.L. Drusano Prevention of resistance: a goal for dose selection for antimicrobial agents Clin Infect Dis 36 Suppl. 1 2003 S42 S50
13. E.M. Jones, and W.L. Howard Streptomycin in the treatment of tuberculosis in children Dis Chest 16 1949 744 760
14. S. Pagkalis, E. Mantadakis, M.N. Mavros, C. Ammari, and M.E. Falagas Pharmacological considerations for the proper clinical use of aminoglycosides Drugs 71 2011 2277 2294
15. D.J. Touw, E.M. Westerman, and A.J. Sprij Therapeutic drug monitoring of aminoglycosides in neonates Clin Pharmacokinet 48 2009 71 88
16. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 155 1987 93 99
17. S.A. Zelenitsky, G.K. Harding, S. Sun, K. Ubhi, and R.E. Ariano Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis J Antimicrob Chemother 52 2003 668 674
18. A.D. Kashuba, A.N. Nafziger, G.L. Drusano, and J.S. Bertino Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria Antimicrob Agents Chemother 43 1999 623 629
19. A.F. Mohamed, E.I. Nielsen, O. Cars, and L.E. Friberg Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants Antimicrob Agents Chemother 56 2012 179 188
20. S.C. Rao, R. Srinivasjois, R. Hagan, and M. Ahmed One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates Cochrane Database Syst Rev 11 2011 CD0058091
21. F. Rougier, D. Claude, M. Maurin, and P. Maire Aminoglycoside nephrotoxicity Curr Drug Targets Infect Disord 4 2004 153 162
22. A.R. Beaubien, S. Desjardins, E. Ormsby, A. Bayne, K. Carrier, and M.J. Cauchy et al. Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels Am J Otolaryngol 10 1989 234 243
23. M. Zappitelli, B.S. Moffett, A. Hyder, and S.L. Goldstein Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study Nephrol Dial Transplant 26 2011 144 150
24. C. Bartal, A. Danon, F. Schlaeffer, K. Reisenberg, M. Alkan, and R. Smoliakov et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial Am J Med 114 2003 194 198
25. N.A. van Lent-Evers, R.A. Mathot, W.P. Geus, B.A. van Hout, and A.A. Vinks Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis Ther Drug Monit 21 1999 63 73
26. M.E.I. Nielsen, M. Sandström, P.H. Honoré, U. Ewald, and L.E. Friberg Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study Clin Pharmacokinet 48 2009 253 263
27. D.S. Streetman, A.N. Nafziger, C.J. Destache, and J.S. Bertino Individualized pharmacokinetic monitoring results in less aminoglycoside- associated nephrotoxicity and fewer associated costs Pharmacotherapy 21 2001 443 451
28. M. Neely, and R. Jelliffe Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician J Clin Pharmacol 50 2010 842 847
29. E. Rey, J.M. Tréluyer, and G. Pons Drug disposition in cystic fibrosis Clin Pharmacokinet 35 1998 313 329
30. D.J. Touw, A.A. Vinks, J.W. Mouton, and A.M. Horrevorts Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions Clin Pharmacokinet 35 1998 437 459
31. W. Lam, J. Tjon, W. Seto, A. Dekker, C. Wong, and E. Atenafu et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients J Antimicrob Chemother 59 2007 1135 1140
32. A.R. Smyth, and J. Bhatt Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis Cochrane Database Syst Rev 1 2010 CD002009
33. P.A. Flume, P.J. Mogayzel Jr., K.A. Robinson, C.H. Goss, R.L. Rosenblatt, and R.J. Kuhn et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations Am J Respir Crit Care Med 180 2009 802 808
34. O. Burkhardt, C. Lehmann, R. Madabushi, V. Kumar, H. Derendorf, and T. Welte Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 58 2006 822 829
35. Z. Tozuka, and T. Murakawa β-Lactam pharmacodynamics C.H. Nightingale, P.G. Ambrose, G.L. Drusano, T. Murakawa, Antimicrobial pharmacodynamics in theory and clinical practice 2nd ed. 2007 CRC Press New York, NY 129 146
36. K. Ampofo, and C.L. Byington Streptococcus pneumoniae S.S. Long, L.K. Pickering, C.G. Prober, Principles and practice of pediatric infectious disease 4th ed. 2012 Churchill Livingstone Edinburgh 721 728
37. W.A. Craig, and D. Andes Pharmacokinetics and pharmacodynamics of antibiotics in otitis media Pediatr Infect Dis J 15 1996 255 259
38. D.M. Canafax, Z. Yuan, T. Chonmaitree, K. Deka, H.Q. Russlie, and G.S. Giebink Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media Pediatr Infect Dis J 17 1998 149 156
39. K. Seikel, S. Shelton, and G.H. McCracken Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media Pediatr Infect Dis J 17 1998 969 970
40. T. Gudnason, F. Gudbrandsson, F. Barsanti, and K.G. Kristinsson Penetration of ceftriaxone into the middle ear fluid of children Pediatr Infect Dis J 17 1998 258 260
41. S.K. Kasiakou, K.R. Lawrence, N. Choulis, and M.E. Falagas Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters Drugs 65 2005 2499 2511
42. J.D. Courter, J.L. Kuti, J.E. Girotto, and D.P. Nicolau Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population Pediatr Blood Cancer 53 2009 379 385
43. J.W. Mouton, and A.A. Vinks Continuous infusion of β-lactams Curr Opin Crit Care 13 2007 598 606
44. K.A. Bauer, J.E. West, J.M. O'Brien, and D.A. Goff Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections Antimicrob Agents Chemother 57 2013 2907 2912
45. M.C. Walker, W.M. Lam, and K.B. Manasco Continuous and extended infusions of β-lactam antibiotics in the pediatric population Ann Pharmacother 46 2012 1537 1546
46. E. Lowdin, I. Odenholt, and O. Cars In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis Antimicrob Agents Chemother 42 1998 2739 2744
47. M.J. Rybak The pharmacokinetic and pharmacodynamic properties of vancomycin Clin Infect Dis 42 Suppl. 1 2006 S35 S39
48. J.D. Knudsen, K. Fuursted, S. Raber, F. Espersen, and N. Frimodt-Moller Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection Antimicrob Agents Chemother 44 2000 1247 1254
49. E.D. Hermsen, G.H. Ross, and J.C. Rotschafer Glycopeptide pharmacodynamics C.H. Nightingale, P.G. Ambrose, G.L. Drusano, T. Murakawa, Antimicrobial pharmacodynamics in theory and clinical practice 2nd ed. 2007 CRC Press New York, NY 189 215
50. R. Kullar, S.L. Davis, D.P. Levine, and M.J. Rybak Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets Clin Infect Dis 52 2011 975 981
51. P.A. Moise-Broder, A. Forrest, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 2004 925 942
52. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, and R.J. Gorwitz et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Clin Infect Dis 52 2011 285 292
53. M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, and M. Billeter et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
54. A. Frymoyer, A.L. Hersh, L.Z. Benet, and B.J. Guglielmo Current recommended dosing of vancomycin for children with invasive methicillin- resistant Staphylococcus aureus infections is inadequate Pediatr Infect Dis J 28 2009 398 402
55. A. Frymoyer, A.L. Hersh, Z. Coralic, L.Z. Benet, and B. Joseph Guglielmo Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation Clin Ther 32 2010 534 542
56. R.F. Chhim, S.R. Arnold, and K.R. Lee Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive staphylococcal infections J Pediatr Infect Dis Soc 2 2013 259 262
57. A. Frymoyer, B.J. Guglielmo, and A.L. Hersh Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections Pediatr Infect Dis J 32 2013 1077 1079
58. J. Le, J.S. Bradley, W. Murray, G.L. Romanowski, T.T. Tran, and N. Nguyen et al. Improved vancomycin dosing in children using area under the curve exposure Pediatr Infect Dis J 32 2013 e155 e163
59. A. Hahn, and A.A. Vinks Lower vancomycin serum concentrations might not be the answer Pediatr Infect Dis J 32 2013 1403 1404
60. C.B. Creech, D.S. Kernodle, A. Alsentzer, C. Wilson, and K.M. Edwards Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children Pediatr Infect Dis J 24 2005 617 621
61. M. McCracken, A. Wong, R. Mitchell, D. Gravel, J. Conly, and J. Embil et al. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009 J Antimicrob Chemother 68 2013 1505 1509
62. C.A. DiazGranados, S.M. Zimmer, M. Klein, and J.A. Jernigan Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clin Infect Dis 41 2005 327 333
63. P. Dehghanyar, C. Bürger, M. Zeitlinger, F. Islinger, F. Kovar, and M. Müller et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses Antimicrob Agents Chemother 49 2005 2367 2371
64. F. Traunmüller, M.V. Schintler, S. Spendel, M. Popovic, O. Mauric, and E. Scharnagl et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections Int J Antimicrob Agents 36 2010 84 86
65. T. Gee, R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise Pharmacokinetics and tissue penetration of linezolid following multiple oral doses Antimicrob Agents Chemother 45 2001 1843 1846
66. S.L. Kaplan, J.G. Deville, R. Yogev, M.R. Morfin, E. Wu, and S. Adler et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children Pediatr Infect Dis J 22 2003 677 686
67. E. Chiappini, C. Conti, L. Galli, and M. de Martino Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review Clin Ther 32 2010 66 88
68. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
69. C.R. Rayner, A. Forrest, A.K. Meagher, M.C. Birmingham, and J.J. Schentag Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme Clin Pharmacokinet 42 2003 1411 1423
70. C.F. Dailey, C.L. Dileto-Fang, L.V. Buchanan, M.P. Oramas-Shirey, D.H. Batts, and C.W. Ford et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 2304 2308
71. M.P. Oramas-Shirey, L.V. Buchanan, C.L. Dileto-Fang, C.F. Dailey, C.W. Ford, and D.H. Batts et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model J Antimicrob Chemother 47 2001 349 352
72. G.L. Jungbluth, I.R. Welshman, and N.K. Hopkins Linezolid pharmacokinetics in pediatric patients: an overview Pediatr Infect Dis J 22 Suppl. 2003 S153 S157
73. G.L. Kearns, S.M. Abdel-Rahman, J.L. Blumer, M.D. Reed, L.P. James, and R.F. Jacobs et al. Single dose pharmacokinetics of linezolid in infants and children Pediatr Infect Dis J 19 2000 1178 1184
74. C. Adembri, S. Fallani, M.I. Cassetta, S. Arrigucci, A. Ottaviano, and P. Pecile et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion Int J Antimicrob Agents 31 2008 122 129
75. H. Dong, X. Wang, Y. Dong, J. Lei, H. Li, and H. You et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients Int J Antimicrob Agents 38 2011 296 300
76. D.J. Touw Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis Pharm World Sci 20 1998 149 160
77. R.P. Santos, C.B. Prestidge, M.E. Brown, B. Urbancyzk, D.K. Murphey, and C.M. Salvatore et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis Pediatr Pulmonol 44 2009 148 154
78. T. Sasaki, H. Takane, K. Ogawa, S. Isagawa, T. Hirota, and S. Higuchi et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients Antimicrob Agents Chemother 55 2011 1867 1873
79. Y. Hiraki, Y. Tsuji, M. Hiraike, N. Misumi, K. Matsumoto, and K. Morita et al. Correlation between serum linezolid concentration and the development of thrombocytopenia Scand J Infect Dis 44 2012 60 64
80. Y. Tsuji, Y. Hiraki, K. Matsumoto, A. Mizoguchi, T. Kobayashi, and S. Sadoh et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction J Infect Chemother 17 2011 70 75
81. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
82. US Centers for Disease Control and Prevention (CDC) Antibiotic resistance threats in the United States, 2013 2013 US Department of Health and Human Services Washington, DC
83. A.A. Vinks The application of population pharmacokinetic modeling to individualized antibiotic therapy Int J Antimicrob Agents 19 2002 313 322